Vmt diagnostic of parkinson disease
This presentation is the property of its rightful owner.
Sponsored Links
1 / 23

VMT Diagnostic of Parkinson Disease PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

VMT Diagnostic of Parkinson Disease. You do not have to be a famous boxer or a successful movie star to be concerned about Parkinson. Highlights. Medical device - Diagnostic, simple PC based + internet analysis. Addressing the dire need for effective PD screening test.

Download Presentation

VMT Diagnostic of Parkinson Disease

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Vmt diagnostic of parkinson disease

VMTDiagnostic of Parkinson Disease

You do not have to be a famous boxer or a successful movie star to be concerned about Parkinson



  • Medical device - Diagnostic, simple PC based + internet analysis.

  • Addressing the dire need for effective PD screening test.

  • Early diagnosis leads to drug treatment that may delay the deterioration of life quality.

  • Competitive advantage over current manual solutions.

  • Strong value proposition for patients, neurologists and payers (deferring costly care).

  • Large target market- many billions in direct and indirect cost.

  • US Patent 5,772,611, approved in 1998.

  • FDA clearance 510(k) - “evaluation of visuo-motor performance disturbances”.

  • Working Prototype

  • Extensive data base with hundreds of test results

  • Time to Market – Less then a year.




  • VMT (Visuo-Motor-test) method was developed by Prof. Hocherman, of the faculty of medicine at the Technion.

  • Prof. Hocherman has been involved in basic brain research for over 25 years.

  • VMT was developed within the framework of his research on neurological motor control.

  • The technology and the IP rights are owned by a group of four individuals, Prof. Hocherman included.


Parkinson disease

Parkinson Disease

  • Parkinson’s disease is the second most common progressive neurodegenerative disorder, after Alzheimer’s disease.

  • ~1.5 million Americans are currently diagnosed with PD and 60,000 new cases are diagnosed each year.

  • More than 2% of the population aged over 65 years are affected.

  • 5%-10% of patients with PD are misdiagnosed (have Parkinson's but are told they have something else),


Cost of pd direct and indirect

Cost of PD - direct and indirect

  • The financial cost of Parkinson’s Disease to individuals, government and society combined is in the order of $24 billion per year.

  • The study finds that indirect costs - e.g. disability payments by government and insurance plans and lost income due to forced early retirement are $15,000 per patient per year.

  • The direct costs of medicines, surgery, doctor visits, hospitals and nursing homes are $8,800 per patient per year.


Parkinson neurological degenerative disease

Parkinson Neurological Degenerative Disease

  • The dopaminergic neurons in the Substantia Nigra are gradually depleted and the levels of Dopamine secretion are diminishing.

  • The lack of Dopamine hormones has a devastating effect on motor, cognitive functions & emotional state.


Vmt product overview

VMTProduct - Overview

  • The enclosure holds the digitizer at elbow’s level and supports the computer monitor, bringing it to eye level.

  • It is designed to allow free hand movement across the digitizer’s plane, while hiding the subject's hand from view.

The product operation

The product - operation


    • A path is displayed on screen.

    • The subject moves the cursor along the entire path, as accurately as possible.


    • A target circle moves along the path, at a predeterminedspeed.

    • The subject has to maintain the cursor within the moving target.


The product operation1

The product - operation

Data analysis complex parameters

Data Analysis - complex parameters

  • The algorithm analyzes and scores the performance in independent tests, comparing Left & Right arms:

    • Test Time.

    • (*)Directional Error (DirEr).

    • (*)Mean percent time of DirEr>50%.

    • Distance from Path.

    • Velocity of hand movement.

    • (*)Number of tracking interruptions.

  • While some of these parameters are standard, the marked (*) measures are unidue to the present system and are protected by patent.



Differential diagnosis of pd

Differential diagnosis of PD

  • The VMT was tested on various groups:

    • Early vs. advance PD patients

    • PD Vs. Essential Tremor patients

    • PD Vs. Normal subjects


Current methods for diagnosis of pd

Current methods for diagnosis of PD

UPDRS is the standard manual scale based on

performance and cognitive tasks. It takes 20-30 min of the neurologist time to complete the test.

SPECT Imaging

Dopamine uptake ligand beta-CIT, a SPECT agent is the most sensitive of biomarkers for the diagnosis of Parkinson's disease.

Beta-CIT targets the dopamine transporter on the dopamine neuronal terminals and quantifies the loss of those terminals.

Clinical applications

Clinical Applications

  • Parkinson

    • Screening for early phase PD patients.

    • Differential diagnosis of PD Vs. Essential Tremor and potentially other cognitive & motor dysfunctions.

    • Optimization of drug treatment for PD patients.

  • Non-Parkinson

    • Evaluation of attention disorders (ADD/ADHD).


Neuroprotection in parkinson s disease

Neuroprotection in Parkinson’s Disease

  • Written by Prof. Shraga Hocherman, :

    If a “holy grail” exists in the context of Parkinson’s disease (PD) there is no doubt that it would be a treatment that can slow, stop or even reverse the degeneration of neurons whose death causes the disease

  • Drugs that treat PD symptoms are available, which offer small to modest degree of neuroprotection.

  • New approaches that offer great promise are currently being tested, based on cell biology and genetic engineering.


Drug treatment disease modification

Drug Treatment - Disease Modification

Care giver or

Nursing home

Early diagnosis of PD

Drug treatment

delays symptoms


of active life


Conclusions from hocherman s publications based on more then 400 patients

Conclusions from Hocherman’s Publicationsbased on more then 400 patients

  • VMT test requires high-level motor planning and cognitive capabilities that are not assessed by the standard diagnostic test - the UPDRS.

  • VisuoMotor coordination of hand movements requires complex cognitive skills, controlling movement direction and velocity. A failure of these high-level motor control systems may occur early in the disease and may even precede the occurrence of motor symptoms.

  • The performance in visuo motor coordination test (VMT) is impaired in early PD patients, either pharmacologically treated or untreated.

  • VMT system maydifferentiate between Essential Tremor patients who may later develop PD and those who wouldn’t.

  • Impaired VMT is a pertinent indication for further SPECT imaging in patients with ET, in order to establish a diagnosis of incipient PD.

  • VMT appears to be a promising, inexpensive and friendly adjunct to the diagnosis of PD.


Interviews with 3 experts on pd

Interviews with 3 experts on PD

  • Prof. M Youdim - Technion Pharmacology: “Drugs for slowing the deterioration of PD are expected soon (Rasagiline), early detection and treatment are critical”.

  • Prof. H. Bergman - Neurological Physiology, Hadassah: “out of all possible indication, early detection is most important”.

  • Dr. Sharon, Neurologist , Shiba Medical center, Movement Disorders “for PD patients, no single diagnostic modality can replace all other tests, but for monitoring the effects of medicated PD patients, VMT may serve as a objective quantitative tool”.


Competitive landscape preliminary

Competitive landscape (preliminary)

  • No commercial products for the diagnosis or screening of PD.

  • Existing methods :

    • UPDRS - is the standard manual scale based on performance and cognitive tasks.

    • SPECT & pet CT - both imaging modalities are suggested for evaluating the # of lost neurons.

    • Olfactory - research level claiming that the lost of smelling capability is indicative to PD.




  • VMT is a breakthrough computer based diagnostic procedure encompasses a highly desirable diagnostic tool in the movement disorders clinic. There is not a similar system in the market and the comparison is made vs. the traditional diagnostic methods which are time consuming, less accurate and do not provide quantified results:

    • Sensitive and objective system that minimizes false first and second degree errors.

    • Reliable differential diagnosis between PD and its main alternative condition (essential tremor).

    • Provides quantitative estimation of the patient's condition.

    • Cost and time savings - Can be operated by a nurse/technician.

    • Desk top and inexpensive.

    • Easy to install and use.

Adhd attention disorder how vmt technology can be used for such an application

ADHD - Attention DisorderHow VMT Technology can be used for such an application

Shraga Hocherman, Emanuel Tirosh, Sharon Dobrovski

Technion, Faculty of Medicine

Adhd future development background 1

ADHD Future DevelopmentBackground 1

  • Inattention is one of the basic components of ADHD pathology.

  • ADHD diagnosis relies on daily parents\teachers observations of the child’s behavior, and on a clinical interview, but does not include specific testing of attentional functionality.

  • Behavioral impairments that lead to a diagnosis of ADHD derive in many cases from deficits that are not related to attention.

Basic test description

Basic-Test description

  • Basic Test: Move a “mouse” controlled cursor so that it remains within a 1cm target circle that moves along a sinusoidal path from one end of the screen to the other.

  • Loss of the target causes the later to stop in place until re-entered by the cursor.

  • Performance Criteria:Number of target-losing events (Tracking interruptions).Cumulative time of tracking interruptions.Distance from target center.Lateral deviation from the target’s path.Instantaneous directional error.

  • Measurements resolution: 1 millisecond; 0.05 millimeter.

Testing with distraction

Testing with distraction

  • Performance under distraction: Target distracters & Cursor distracters.

  • The number and combination of distracters determines the attentional demand of the subject.

  • Assessment of the cost imposed by the attentional load by computing the performance difference between the distracted and the basic task.

  • Low distraction level: 1 target distracter + 1 cursor distracter.

  • High distraction level: 3 target distracters + 3 cursor distracters.

  • Login